Incidence and risk factors for AIDS-related mortality in HIV patients in China: a cross-sectional study

BMC Public Health

Ning Wang¹  Rongbin Yu²  Zhihang Peng²  Wei Guo¹  Qing Wang²  Jessie Norris¹  Peng Huang²  Lu Wang¹  Hui Zheng² 

[1] National Center for AIDS/STD Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China;Department of Epidemiology and Biostatistics, School of Public Health, Nanjing Medical University, Nanjing, Jiangsu 211166, China

关键词: China;    Mortality;    Highly active antiretroviral treatment;    HIV/AIDS;   

Others  :  1128648
DOI  :  10.1186/1471-2458-14-831

 received in 2014-02-24, accepted in 2014-07-03,  发布年份 2014

【 摘 要 】

Background

To estimate the incidence and risk factors for mortality in HIV-1-infected patients in China.

Methods

Information on AIDS-related deaths was collected from the Chinese Center for Disease Control and Prevention’s Disease Surveillance Information Reporting System and AIDS Prevention and Control Information System.

Results

A total of 379,348 HIV cases were recorded in the databases from 2006. Among those, 138,288 patients were reported as having developed AIDS and 72,616 (19%) died of AIDS after data was extracted from the databases in January 2011. Mortality was higher among those patients aged 50 years old or older (AOR: 3.41, CI: 1.47-7.91) who had been infected by intravenous drug use (AOR: 1.65, CI: 1.28-2.14) or blood transfusion/donation (AOR: 2.18: 1.18-3.99). Compared to patients who had not initiated highly active antiretroviral therapy (HAART), those who had initiated HAART were more likely to have a long interval of time between infection confirmation and AIDS-related death.

Conclusions

The effective reduction of AIDS mortality could be improved through timely treatment.

【 授权许可】

   
2014 Zheng et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Ministry of Health of The People’s Republic of China: 2012 China AIDS Response Progress Report. 2012. http://www.unaids.org/en/dataanalysis/knowyourresponse/countryprogressreports/2012countries/ce_CN_Narrative_Report[1].pdf webcite
• [2]Jiang ZS, Jiang JN: Research progress in death risk factors of HIV infector and AIDS patients. Inter J Epidemiol Infect Dis 2012, 39(1):63-67.
• [3]Walensky RP, Wood R, Weinstein MC, Martinson NA, Losina E, Fofana MO, Goldie SJ, Divi N, Yazdanpanah Y, Wang B, Paltiel AD, Freedberg KA: Scaling up antiretroviral therapy in South Africa: the impact of speed on survival. J Infect Dis 2008, 197(9):1324-1332.
• [4]Palella FJ, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, Aschman DJ, Holmberg SD: Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998, 338(13):853-860.
• [5]The Antiretroviral Therapy Cohort Collaboration: Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies. Lancet 2008, 372(9635):293-299.
• [6]Sungkanuparph S, Chakriyanuyok T, Butthum B: Antiretroviral therapy in AIDS patients with CMV disease: impact on the survival and long-term treatment outcome. J Infect 2008, 56(1):40-43.
• [7]Detels R, Tarwater P, Phair JP, Margolick J, Riddler SA, Munoz A: Effectiveness of potent antiretroviral therapies on the incidence of opportunistic infections before and after AIDS diagnosis. AIDS 2001, 15(3):347-355.
• [8]Palella JF, Chmiel JS, Moorman AC, Holmberg SD: Durability and predictors of success of highly active antiretroviral therapy for ambulatory HIV-infected patients. AIDS 2002, 16(12):1617-1626.
• [9]Moore RD, Chaisson RE: Natural history of HIV infection in the era of combination antiretroviral therapy. AIDS 1999, 13(14):1933-1942.
• [10]Mocroft A, Ledergerber B, Katlama C, Kirk O, Reiss P, D’Arminio MA, Knysz B, Dietrich M, Phillips AN, Lundgren JD: Decline in the AIDS and death rates in the EuroSIDA study: an observational study. Lancet 2003, 362(9377):22-29.
• [11]Porter K, Babiker A, Bhaskaran K, Darbyshire J, Pezzotti P, Walker AS: Determinants of survival following HIV-1 seroconversion after the introduction of HAART. Lancet 2003, 362(9392):1267-1274.
• [12]Palella FJ, Baker RK, Moorman AC, Chmiel JS, Wood KC, Brooks JT, Holmberg SD: Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study. J Acquir Immune Defic Syndr 2006, 43(1):27-34.
• [13]Bozzette SA, Joyce G, Mccaffrey DF, Leibowitz AA, Morton SC, Berry SH, Rastegar A, Timberlake D, Shapiro MF, Goldman DP: Expenditures for the care of HIV-infected patients in the era of highly active antiretroviral therapy. N Engl J Med 2001, 344(11):817-823.
• [14]Egger M, May M, Chene G, Phillips AN, Ledergerber B, Dabis F, Costagliola D, D’Arminio MA, de Wolf F, Reiss P, Lundgren JD, Justice AC, Staszewski S, Leport C, Hogg RS, Sabin CA, Gill MJ, Salzberger B, Sterne JA: Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet 2002, 360(9327):119-129.
• [15]Mocroft A, Brettle R, Kirk O, Blaxhult A, Parkin JM, Antunes F, Francioli P, D’Arminio MA, Fox Z, Lundgren JD: Changes in the cause of death among HIV positive subjects across Europe: results from the EuroSIDA study. AIDS 2002, 16(12):1663-1671.
• [16]Murphy EL, Collier AC, Kalish LA, Assmann SF, Para MF, Flanigan TP, Kumar PN, Mintz L, Wallach FR, Nemo GJ: Highly active antiretroviral therapy decreases mortality and morbidity in patients with advanced HIV disease. Ann Intern Med 2001, 135(1):17-26.
• [17]Zhang F, Dou Z, Ma Y, Zhao Y, Liu Z, Bulterys M, Chen RY: Five-year outcomes of the China National Free Antiretroviral Treatment Program. Ann Intern Med 2009, 151(4):241-251. 52
• [18]Fleishman JA, Hellinger FH: Recent trends in HIV-related inpatient admissions 1996–2000: a 7-state study. J Acquir Immune Defic Syndr 2003, 34(1):102-110.
• [19]Hogg RS, Yip B, Chan KJ, Wood E, Craib KJ, O’Shaughnessy MV, Montaner JS: Rates of disease progression by baseline CD4 cell count and viral load after initiating triple-drug therapy. JAMA 2001, 286(20):2568-2577.
• [20]Jian L, Ye M, Fu-Jie Z: HIV antiretroviral therapy mode and the current situation in China. Chin J AIDS STD (In Chinese) 2012, 18(10):711-714.
• [21]Dai Y, Qiu ZF, Li TS, Han Y, Zuo LY, Xie J, Ma XJ, Liu ZY, Wang AX: Clinical outcomes and immune reconstitution in 103 advanced AIDS patients undergoing 12-month highly active antiretroviral therapy. Chin Med J (Engl) 2006, 119(20):1677-1682.
• [22]Etard JF, Ndiaye I, Thierry-Mieg M, Gueye NF, Gueye PM, Laniece I, Dieng AB, Diouf A, Laurent C, Mboup S, Sow PS, Delaporte E: Mortality and causes of death in adults receiving highly active antiretroviral therapy in Senegal: a 7-year cohort study. AIDS 2006, 20(8):1181-1189.
• [23]Seyler C, Anglaret X, Dakoury-Dogbo N, Messou E, Toure S, Danel C, Diakite N, Daudie A, Inwoley A, Maurice C, Tonwe-Gold B, Rouet F, N’Dri-Yoman T, Salamon R: Medium-term survival, morbidity and immunovirological evolution in HIV-infected adults receiving antiretroviral therapy, Abidjan, Cote d’Ivoire. Antivir Ther 2003, 8(5):385-393.
• [24]Lawn SD, Bekker LG, Myer L, Orrell C, Wood R: Cryptococcocal immune reconstitution disease: a major cause of early mortality in a South African antiretroviral programme. AIDS 2005, 19(17):2050-2052.
• [25]Lawn SD, Myer L, Bekker LG, Wood R: Burden of tuberculosis in an antiretroviral treatment programme in sub-Saharan Africa: impact on treatment outcomes and implications for tuberculosis control. AIDS 2006, 20(12):1605-1612.
• [26]Wanyenze RK, Kamya MR, Fatch R, Mayanja-Kizza H, Baveewo S, Sawires S, Bangsberg DR, Coates T, Hahn JA: Missed opportunities for HIV testing and late-stage diagnosis among HIV-infected patients in Uganda. PLoS One 2011, 6(7):e21794.
• [27]Hosegood V, Vanneste AM, Timaeus IM: Levels and causes of adult mortality in rural South Africa: the impact of AIDS. AIDS 2004, 18:663-671.
• [28]Ministry of Health of the People’s Republic of China: Estimated that China’s AIDS epidemic in 2011. Chin J AIDS STD 2012, 18(1):1-5.
• [29]Wang L, Qin QQ, Ding ZW, Li PL, Hei FX, Wang LY, Chen FF: Current case reporting of HIV/AIDS epidemic in China. Chin J AIDS STD 2011, 17(3):275-278.
• [30]Zhang FJ, Dou ZH, Ma Y, Zhang Y, Zhao Y, Zhao DC, Zhou ST, Marc B, Zhu H, Chen RY: Effect of earlier initiation of antiretroviral treatment and increased treatment coverage on HIV-related mortality in China: a national observational cohort study. Lancet Infect Dis 2011, 11(7):516-524.
• [31]Janssen W, Trubner K, Puschel K: Death caused by drug addiction: a review of the experiences in Hamburg and the situation in the Federal Republic of Germany in comparison with the literature. Forensic Sci Int 1989, 43(3):223-237.
• [32]Krentz HB, Kliewer G, Gill MJ: Changing mortality rates and causes of death for HIV-infected individuals living in Southern Alberta, Canada from 1984 to 2003. HIV Med 2005, 6(2):99-106.
• [33]Zhang FJ, Dou ZH, Yu L, Xu JH, Jiao JH, Wang N, Ma Y, Zhao Y, Zhao HX, Chen RY: The effect of highly active antiretroviral therapy on mortality among HIV-infected former plasma donors in China. Clin Infect Dis 2008, 47(6):825-833.
• [34]Dou ZH, Chen RY, Wang Z, Ji GP, Peng GP, Qiao XC, Fu JH, Meng XD, Bulterys M, Ma Y, Zhao Y, Wang N, Zhang FJ: HIV-infected former plasma donors in rural Central China: from infection to survival outcomes, 1985–2008. PLoS One 2010, 5(10):e13737.
• [35]Wu Z, Xu J, Liu E, Mao Y, Xiao Y, Sun X, Liu Y, Jiang Y, McGoogan JM, Dou Z, Mi G, Wang N, Sun J, Liu Z, Wang L, Rou K, Pang L, Xing W, Xu J, Wang S, Cui Y, Li Z, Bulterys M, Lin W, Zhao J, Yip R, Wu Y, Hao Y, Wang Y: HIV and syphilis prevalence among men who have sex with men: a cross-sectional survey of 61 cities in China. Clin Infect Dis 2013, 58(6):298-309.
• [36]Guo H, Wei JF, Yang H, Huan X, Tsui SK, Zhang C: Rapidly increasing prevalence of HIV and syphilis and HIV-1 subtype characterization among men who have sex with men in Jiangsu, China. Sex Transm Dis 2009, 36:120-125.
• [37]Mocroft A, Vella S, Benfield TL, Chiesi A, Miller V, Gargalianos P, d'Arminio Monforte A, Yust I, Bruun JN, Phillips AN, Lundgren JD: Changing patterns of mortality across Europe in patients infected with HIV-1. EuroSIDA Study Group. Lancet 1998, 352:1725-1730.
• [38]Smit C, Geskus R, Uitenbroek D, Mulder D, Van den Hoek A, Coutinho RA, Prins M: Declining AIDS mortality in Amsterdam: contributions of declining HIV incidence and effective therapy. Epidemiology 2004, 15:536-542.
• [39]Keiser O, Taffe P, Zwahlen M, Battegay M, Bernasconi E, Weber R, Rickenbach M: All cause mortality in the Swiss HIV Cohort Study from 1990 to 2001 in comparison with the Swiss population. AIDS 2004, 18:1835-1843.
• [40]Detels R, Munoz A, McFarlane G, Kingsley LA, Margolick JB, Giorgi J, Schrager LK, Phair JP: Effectiveness of potent antiretroviral therapy on time to AIDS and death in men with known HIV infection duration. Multicenter AIDS Cohort Study Investigators. JAMA 1998, 280:1497-1503.
• [41]Jiang HY, Fu J, Liu JH, Gong JP, Lu FB: Qualitative study of AIDS-related discrimination among the people with HIV/AIDS. Mod Prev Med (In Chinese) 2010, 37(5):867-875.
• [42]Holtgrave DR: Causes of the decline in AIDS deaths, United States, 1995–2002: prevention, treatment or both. Int J STD AIDS 2005, 16(12):777-781.
• [43]Li TS: How to improve the anti-HIV treatment success in China. Natl Med J China 2011, 91(21):1441-1442.